



Our 2023 Report

Janssen

Janssen funded £25,000 worth of research undertaken by UCL in order to reduce delays to diagnosis of blood cancer.

Gilead

£45,380 worth of funding was directed towards the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients.

Takeda

Takeda directed £45,380 worth of funding towards the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients.

Bristol Myers Squibb

£120,000 went towards supporting the Covid-19 Vaccine Research Collaborative. Another £35,000 worth of funding was directed at the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients.

Roche

Roche funded £25,000 towards health information transformation.

Incyte

£15,000 went towards supporting our Clinical Trials Support Service.

AstraZeneca

AstraZeneca provided £15,000 to help fund a fixed-term Covid Policy Offer job role.

Kyowa Kirin

£5,000 went towards supporting our Clinical Trials Support Service.

B

GSK

GSK funded £20,000 worth of research based on data from Covid treatment centres.